크레센트 바이오파마(CBIO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $17.32 (+3.28%), 시가총액 $0.51B, 52주 최저~최고 $0.16 ~ $26.98.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
크레센트 바이오파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
크레센트 바이오파마의 현재 주가는 $17.32 (+3.28%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
크레센트 바이오파마의 시가총액은 약 $0.51B입니다.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprieta